Scholarlink

<p>Trifluridine/tipiracil (FTD/TPI) has shown efficacy in treating advanced colorectal and gastric cancers. Although renal injury due to FTD/TPI is rare, its renal effects have not been well documented. We present the case of a 74-year-old man with metastatic colon cancer who developed nephrotic syndrome with hematuria after transitioning from a regimen of irinotecan, S-1, and bevacizumab to FTD/TPI. Renal biopsy revealed IgA nephropathy with glomerular microangiopathy (GMA). His condition improved with steroid therapy. To our knowledge, this is the first documented case of nephrotic syndrome associated with FTD/TPI. Renal toxicity should be monitored through urinalysis during FTD/TPI treatment.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Nephrotic syndrome after switching from irinotecan, S-1, and bevacizumab combination to trifluridine/tipiracil

  • 期刊论文

  • 发表日期：

    2025年7月10日

查看全文
  • Jun Takami,
  • Yuta Nakano,
  • Eriko Harada,
  • Shota Nakakuma,
  • Ryosuke Kawamoto,
  • Eisaku Ito,
  • Kayoko Matsukawa

摘要

Trifluridine/tipiracil (FTD/TPI) has shown efficacy in treating advanced colorectal and gastric cancers. Although renal injury due to FTD/TPI is rare, its renal effects have not been well documented. We present the case of a 74-year-old man with metastatic colon cancer who developed nephrotic syndrome with hematuria after transitioning from a regimen of irinotecan, S-1, and bevacizumab to FTD/TPI. Renal biopsy revealed IgA nephropathy with glomerular microangiopathy (GMA). His condition improved with steroid therapy. To our knowledge, this is the first documented case of nephrotic syndrome associated with FTD/TPI. Renal toxicity should be monitored through urinalysis during FTD/TPI treatment.